Completed Hemophilia A trials in Japan: Trial Insights

Filters: Condition: Hemophilia A Status: Completed Country / region: Japan Clear all

54 trials match Source: ClinicalTrials.gov registrations

Trials started per year
Category	Trials
2007	1
2008	1
2009	3
2010	4
2011	4
2012	6
2013	4
2014	4
2015	5
2016	2
2017	5
2018	6
2019	2
2020	1
2021	4
2023	1
2024	1

Trials by status
Category	Trials
Completed	54

Top lead sponsors
Category	Trials
Novo Nordisk A/S	20
Baxalta now part of Shire	5
Bayer	5
Hoffmann-La Roche	5
Genzyme, a Sanofi Company	4
Bioverativ Therapeutics Inc.	2
Bioverativ, a Sanofi company	2
CSL Behring	2
Kiminori Kimura, MD	2
Pfizer	2

Top conditions
Category	Trials
Hemophilia A	54
Hemophilia B	12
Blood Coagulation Disorders	2
Blood Coagulation Disorders, Inherited	2
Coagulation Protein Disorders	2
Genetic Diseases, Inborn	2
Genetic Diseases, X-Linked	2
Hematologic Diseases	2
Hemorrhagic Disorders	2
Liver Cirrhosis	2

Trials

Showing 1 to 25 of 54. Each trial links to its page on Pharma Observatory.

A Phase 2 Trial of Foscenvivint in Liver Cirrhosis Patients Caused by HIV/HCV Co-infection With Hemophilia (OP-724-H201) NCT06144086Phase 2CompletedKiminori Kimura, MDStarted 2024
A Research Study Looking at How Safe it is to Switch From Emicizumab to Mim8 in People With Haemophilia A (FRONTIER 5) NCT05878938Phase 3CompletedNovo Nordisk A/SStarted 2023
A Research Study Investigating Mim8 in Adults and Adolescents With Haemophilia A With or Without Inhibitors NCT05053139Phase 3CompletedNovo Nordisk A/SStarted 2021
A Study of TAK-660 in Surgical Procedures for People With Hemophilia A. NCT04941898ObservationalCompletedTakedaStarted 2021
Post-Marketing Surveillance (Use-results Surveillance) With Esperoct® NCT04334057ObservationalCompletedNovo Nordisk A/SStarted 2021
Safety and Tolerability Study of OP-724 in Liver Cirrhosis Patients by HIV/HCV with Hemophilia. NCT04688034Phase 1CompletedKiminori Kimura, MDStarted 2021
Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B NCT03938792Phase 3CompletedPfizerStarted 2020
A Phase 3 Open-label Interventional Study of Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein, Efanesoctocog Alfa (BIVV001), in Patients With Severe Hemophilia A NCT04161495Phase 3CompletedBioverativ, a Sanofi companyStarted 2019
Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX NCT03754790Phase 3CompletedGenzyme, a Sanofi CompanyStarted 2019
A Study Following People With Haemophilia A and B, With or Without Inhibitors, When on Usual Treatment (Explorer™6) NCT03741881ObservationalCompletedNovo Nordisk A/SStarted 2018
A Study to Evaluate Prospective Efficacy and Safety Data of Current FIX Prophylaxis Replacement Therapy in Adult Hemophilia B Subjects (FIX:C≤2%) or Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Subjects (FVIII:C≤1%) NCT03587116Phase 3CompletedPfizerStarted 2018
A Study of Fitusiran in Severe Hemophilia A and B Patients Previously Receiving Factor or Bypassing Agent Prophylaxis NCT03549871Phase 3CompletedGenzyme, a Sanofi CompanyStarted 2018
A Research Study Looking at How a Factor VIII Medicine Called Turoctocog Alfa Pegol (N8-GP) Works in People With Haemophilia A NCT03528551Phase 3CompletedNovo Nordisk A/SStarted 2018
A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients Without Inhibitors NCT03417245Phase 3CompletedGenzyme, a Sanofi CompanyStarted 2018
A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients With Inhibitors NCT03417102Phase 3CompletedGenzyme, a Sanofi CompanyStarted 2018
A Safety, Tolerability, and Pharmacokinetics Study of a Single Intravenous Injection of Recombinant Coagulation Factor VIII Fc - Von Willebrand Factor - XTEN Fusion Protein (rFVIIIFc-VWF-XTEN) (BIVV001) in Previously Treated Adults With Severe Hemophilia A (EXTEN-A) NCT03205163Phase 1/2CompletedBioverativ, a Sanofi companyStarted 2017
A Trial Evaluating Efficacy and Safety of Prophylactic Administration of Concizumab in Patients With Severe Haemophilia A Without Inhibitors NCT03196297Phase 2CompletedNovo Nordisk A/SStarted 2017
ADYNOVATE Drug Use-Results Survey NCT03169972ObservationalCompletedTakedaStarted 2017
Safety, Tolerability, and Pharmacokinetics Study of Turoctocog Alfa Pegol Injected Under the Skin in Patients With Haemophilia A NCT02994407Phase 1CompletedNovo Nordisk A/SStarted 2017
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Emicizumab Given Every 4 Weeks in Participants With Hemophilia A NCT03020160Phase 3CompletedHoffmann-La RocheStarted 2017
A Clinical Trial to Evaluate Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants Without Inhibitors NCT02847637Phase 3CompletedHoffmann-La RocheStarted 2016
A Study of Emicizumab Administered Subcutaneously (SC) in Pediatric Participants With Hemophilia A and Factor VIII (FVIII) Inhibitors NCT02795767Phase 3CompletedHoffmann-La RocheStarted 2016
Patient Functioning and Well-being, Economic, and Clinical Impact of Hemophilia A and Its Treatment NCT02396862ObservationalCompletedBayerStarted 2015
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants With Inhibitors NCT02622321Phase 3CompletedHoffmann-La RocheStarted 2015
A Single Escalating Dose and Multiple Dose Study of BAY 1093884 in Subjects With Severe Hemophilia Types A or B, With or Without Inhibitors NCT02571569Phase 1CompletedBayerStarted 2015

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.

Visit Pharma Observatory